Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid

Journal of Ocular Pharmacology and Therapeutics

Volumn 16, Issue 3, 2000, Pages 217-230

  Beilin, Mark ^a   Neumann, Ron ^a   Belkin, Michael ^b   Green, Keith ^c   Bar Ilan, Amir ^a  

^a PHARMOS LTD   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CLONIDINE; DEXANABINOL; PROPRANOLOL; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; RABBITS AND HARES;

EID: 0034046008     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2000.16.217     Document Type: Article

References (49)

1. Adler, M.W. and Geller, E.B. Ocular effects of Cannabinoids. In Cannabinoids as Therapeutic Agents, Mechoulam, R., ed., CRC Press, Boca Raton, 1986, pp. 51-70.
2. Green, K. Marijuana effects on intraocular pressure. In Glaucoma: Applied Pharmacology in Medical Treatment, Drance, S.M. and Neufeld, A.H., eds., Grune and Stratton, Orlando, 1984, pp. 507-526.
3. Korczyn, A.D. The ocular effects of cannabinoids. Gen. Pharmacol. 11:419-423, 1980.
4. ElSohly, M.A., Harland, E., Murphy, J.C., Wirth, P., and Waller, C.W. Cannabinoids in glaucoma: A primary screening procedure. J. Clin. Pharmacol. 21:4728-4788, 1981.
5. Green, K. Marijuana and the eye: A review. J. Toxicol. Cutan. Ocular Toxicol. 1:3-32, 1982.
6. Green, K., Bigger, J.F., Kim, K., and Bowman, K. Cannabinoid action on the eye as mediated through the central nervous system and local adrenergic activity. Exp. Eye Res. 24:189-196, 1977.
7. Liu, J.H.K. and Dacus, A.C. Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids. Arch. Ophthalmol. 105:245-248, 1987.
8. Green, K. and Kim, K. Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous system. Exp. Eye Res. 23:443-448, 1976.
9. Devane, W.A., Breuer, A., Sheskin, T., Jarbe, T.U.C., Eisen, M.S., and Mechoulam, R. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:2065-2069, 1992.
10. Little, P.J., Compton, D.R., Mechoulam, R., and Martin, B.R. Stereochemical effects of 11-OH-Δ-THC-dimethylheptyl in mice and dogs. Pharmacol. Biochem. Behav. 32:661-666, 1989.
11. Howlett, A.C., Champion, T.M., Wilken, G.H., and Mechoulam, R. Stereochemical effects of 11-OH-Δ-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 29:161-165, 1990.
12. Eshhar, N., Striem, S., and Biegon, A. HU-211, a non-psychotropic cannabinoid, rescues cortical neurons from excitatory amino acid toxicity in culture. Neuroreport 5:237-240, 1993.
13. Feigenbaum, J.J., Bergmann, F., Richmond, S.A., Mechoulam, R., Nadler, V., Kloog, Y., and Sokolovsky, M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-A-aspartate receptor blocker. Proc. Natl. Acad. Sci. 86:9584-9587, 1989.
14. Beilin, M., Aviv, H., Friedman, D., Vered, M., Belkin, M., Neumann, R., Amselem, S., Schwarz, J., and Bar-Ilan, A. HU-211, a novel synthetic, non-psychotropic cannabinoid with ocular hypotensive activity. Invest. Ophthalmol. Vis. Sci. 34(suppl):1113, 1993.
15. Amselem, S., Schwarz, Y., Cohen, A., Wellner, E., Baru, H., Beilin, M., Bar-Ilan, A., Neumann, R., and Friedman, D. Formulation in submicron emulsion of HU-211, a novel synthetic non-psychotropic cannabinoid with ocular hypotensive activity. Pharmaceut. Res. 10(suppl):E-236 (PDD 7246), 1993.
16. Bar-Ilan, A., Baru, H., Beilin, M., Friedman, D., Amselem, S., and Neumann, R. Extended activity and increased bioavailability of indomethacin formulated in submicron emulsion, compared to commercially available formulation. Reg. Immunol. 6:166-168, 1994.
17. Brechue, W.F. and Maren, T.H. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion. Exp. Eye Res. 57:67-78, 1993.
18. Green, K. and Bowman, K. Effect of marihuana derivatives on intraocular pressure in the rabbit. In The Pharmacology of Marihuana, M.C. Braude and S. Szara, eds., Raven Press, New York, 1976, pp. 803-813.
19. Green, K., Symonds, C.M., Oliver, N. W., and Elijah, D.R. Intraocular pressure following systemic administration of cannabinoids. Curr. Eye Res. 4:247-253, 1982.
20. 1-tetrahydrocannabinol on aqueous dynamics and ciliary body permeability in the rabbit. Exp. Eye Res. 15:499-507, 1973.
21. Green, K., Wynn, H., and Padgett D. Effect of Δ-9-tetrahydrocannabinol on ocular blood flow and aqueous humor formation. Exp. Eye Res. 26:65-69, 1978.
22. Colasanti, B. and Gong, H. Effects of cannabinoids on aqueous humor dynamics in the cat. In Marihuana: An International Report, Chesher, G., Consroe, P. and Musty, R. eds., Australian Government Publishing Service, Canberra, 1988, pp. 119-124.
23. Dewey, W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:151-178, 1986.
24. Gerard, C., Mollereau, C., Vassart, G., and Parmentier, M. Nucleotide sequence of human cannabinoid receptor cDNA. Nucleic Add Res. 18:7142, 1990.
25. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., and Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:563-583, 1991.
26. 8-tetrahydrocannabinol in rats and pigeons. J. Pharmacol. Exp. Ther. 250:1000-1005, 1989.
27. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564, 1990.
28. Mechoulam, R., Feigenbaum, J.J., Lander, N., Segal, M., Jarbe, T.U., Hiltunen, A.J., and Consroe, P. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44:762-764, 1988.
29. Nye, J.S., Seltzman, H.H., Pitt, C.G., and Snyder, S.H. High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5′-trimethylammonium-Δ-8-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 34:784-791, 1985.
30. Bloom, A.S. and Hillard, G.J. Cannabinoids, neurotransmitter receptors and brain membranes. In Marijuana 84, Harvey, D.J., ed., IRL Press:Oxford, 1985, pp. 211-231.
31. Devane, W.A., Dysarz, F.A., Johnson, M.R., Melvin, L.S., and Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:605-613, 1988.
32. Lynn, A.B. and Herkenham, M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implication for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1612-1623, 1994.
33. Smith, P.B., Welch, S.P., and Martin, B. Interactions between Δ-9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268:1381-1387, 1994.
34. Vaysse, P.J., Gardner, E.L., and Zukin, R.S. Modulation of rat brain opioid receptors by cannabinoids. J. Pharmacol. Exp. Ther. 241:534-539, 1987.
35. Elridge, J.C. and Landfield, P.W. Cannabinoid interactions with glucocorticoid receptors in rat hippocampus. Brain Res. 534:133-141, 1990.
36. Hillard, C.J. and Bloom, A.S. Δ-9-tetrahydrocannabinol-induced changes in β-adrenergic receptor binding in mouse cerebral cortex. Brain Res. 235:370-377, 1982.
37. Martin, B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:45-74, 1986.
38. Stark, P. and Dews, P.B. Cannabinoids. (II) Cardiovascular effects. J. Pharmacol. Exp. Ther. 214:131-138, 1980.
39. Mechoulam, R. Current status of therapeutic opportunities based on cannabinoid research. An overview. J. Clin. Pharmacol. 21(suppl):2S-7S, 1981.
40. Hodges, L.C., Reggio, P.H., and Green, K. Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. Ophthalmic Res. 29:1-5, 1997.
41. Pate, D.W., Jarvinen, K., Urtti, A., Mahadevan, V., and Jarvinen, T. Effect of CB1 receptor antagonist SR141716A on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 63:2181-2188, 1998.
42. Nadler, V., Mechoulam, R., and Sokolovsky, M. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetracannabinol-1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. 159:43-45, 1993.
43. 2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res. 622:79-85, 1993.
44. Bar-Joseph, A., Berkovich, Y., Greenberger, V., and Biegon, A. Neuroprotective activity of HU-211, a non-psychotropic synthetic cannabinoid. J. Neurochem. 61(suppl):5-6, 1993.
45. 2 adrenoreceptors. Curr. Eye Res. 11:963-970, 1992.
46. 2-receptor subclasses and antiglaucoma efficacy. J. Ocular Pharmacol. 10:359-369, 1994.
47. Sears, M.L. Physiology and pharmacology of alpha and beta receptors in the eye. Surv. Ophthalmol. 33(suppl):451-452, 1989.
48. McAuliffe-Curtin, D. and Buckley, C. Review of alpha adrenoreceptor function in the eye. Eye 3:472-476, 1989.
49. 1) receptors in modulating aqueous humor dynamics. J. Ocular Pharmacol. 10:393-402, 1994.